Chemo before surgery for borderline resectable pancreas cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of chemotherapy drugs (FOLFIRINOX and gemcitabine plus TAMP) given before surgery for borderline resectable pancreatic cancer. The goal is to shrink the tumor and make surgery more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be a specific type called pancreatic ductal adenocarcinoma (PDAC).
- The tumor must be 'borderline resectable', meaning it is near blood vessels but might still be safely removable with surgery.
- You cannot have had any previous treatments for this cancer (like chemo or radiation).
- You must be 18 or older and in relatively good health (able to do your daily activities).
- You must be able to take the chemotherapy drugs gemcitabine and FOLFIRINOX.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (irinotecan liposome, 5-FU, leucovorin, and oxaliplatin) given before and after surgery for people with pancreatic cancer that is on the border of being removable. The goal is to see if this treatment helps shrink the tumor and improve outcomes.
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.